Appeals court sides with Gilead, Kite in CAR-T patent brawl, voiding Bristol Myers’ big $1.2B award
A new twist emerged Thursday in the long-running patent fight between Juno Therapeutics and Gilead’s Kite Pharma over CAR-T technology, one that gets Kite off …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
